Vaccine Analysis for a New Era

As vaccine technologies continue to expand, David Hage explores how analytical methods must evolve to meet growing demands for safety, quality, and activity testing

June 8, 2026
11 min

The Analytical Scientist

Original Source(s)

The Analytical Scientist

Vaccine Analysis for a New Era

June 8, 2026

Related Content

Frontiers In Immunology

Anti-NMDAR and anti-MOG antibody double-positive encephalitis temporally associated with cytomegalovirus detection in cerebrospinal fluid: a case report

by Rujue Guo, Qili Chen, Lingen Kong, Aizheng Huang, Yankun Li, Caiming Li
June 9, 2026

Nature Medicine

Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial

by Justin R. Ortiz, Drishya Kurup, Adam C. Kaufman, Sabrine Ben Hamed, Allison M. LaRocco, Kirsten E. Lyke, Sarah M. Litts, Shrimati Datta, Yuanyuan Liang, Megan F. McGilvray, Jeannie A. Losignor, Jennifer J. Oshinsky, Kari V. Palmer, Ifayet PL Johnson-Mayo, Gabrielle Scher, Uthra Balakumar, Anisha Chandwani, Rekha R. Rapaka, Meagan E. Deming, Joel V. Chua, Christoph Wirblich, Wilbur H. Chen, Kathleen M. Neuzil, Marcela F. Pasetti, Matthias J. Schnell
June 9, 2026

Frontiers In Medicine

Prediction models for the occurrence and mortality of sepsis-associated lung injury: a systematic review and meta-analysis

by Chen Liu, Jian Huo, Yan-Song Li, An-Min Hu, Ting-Ting Ao
June 9, 2026